The Wegovy pill — Novo Nordisk's reformulated oral semaglutide for chronic weight management — launched into the same competitive frame as Lilly's small-molecule Foundayo (orforglipron). Coverage on this site has tracked the launch pricing, distribution channels, and head-to-head comparisons.
Key moves: Amazon Pharmacy expanded access to the oral Wegovy pill with both insurance and cash-pay options; NovoCare priced the 1.5mg starter dose at $149/month and moved the 4mg dose from $149 to $199 effective April 15, 2026; and indirect comparisons suggested oral Wegovy may produce greater weight loss than Foundayo (which leads on HbA1c). Novo's May 6 Q1 print confirmed the launch's strength: DKK 2.26B (~$354M) in Q1 sales — almost 2× the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative US scripts since the January 5 launch. Weekly retail volume was around 113,000 by early May, more than 20× Foundayo's Week 3 reading of 5,612.
Stories here cover the launch tracker, payer coverage, and head-to-head comparisons. See #oral-wegovy, #wegovy, and #foundayo.
Novo Nordisk presented new OASIS 4 subanalyses of the Wegovy pill (oral semaglutide 25 mg) at ECO 2026 on May 13. Nearly one third (29%) of patients were classified as 'early responders' — losing at least 10% body weight by week 16 — and continued treatment to 64 weeks for a mean 21.6% body weight loss vs 13.2% at four months. A separate physical function analysis showed 77.3% of patients with poor baseline physical function achieved clinically meaningful improvement (bending over, standing comfortably, staying active) vs 42.9% on placebo. The data adds to the OASIS 4 February 2026 16.6% mean weight-loss headline by stratifying patients on early response — a likely tool for prescribers thinking about dose escalation and persistence.
An ORION indirect treatment comparison presented at ECO 2026 on May 13 framed the head-to-head competition between Novo's Wegovy pill (oral semaglutide 25 mg) and Lilly's Foundayo (orforglipron 36 mg). The Wegovy pill delivered statistically significant greater mean weight loss than orforglipron, with patients on orforglipron showing approximately 14x higher odds of discontinuing treatment due to gastrointestinal side effects. The May 13 framing complements Novo's Q1 print disclosure that Wegovy holds 65% of all new US GLP-1 prescriptions; CEO Mike Doustdar's CNBC commentary called the moment a 'turnaround situation' for the Danish company. The ORION ITC matters as a prescriber-decision tool given the two compounds are now the only two FDA-approved oral GLP-1s for chronic weight management.
Novo Nordisk Q1 management commentary delivered alongside the ECO 2026 data updates confirmed that the Wegovy pill (oral semaglutide 25 mg) will launch in select international markets in the second half of 2026 with European approval expected before year-end. The international rollout follows the January 5 US launch that delivered DKK 2.26B (~$354M) in Q1 sales — nearly double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and >2M cumulative US prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions; Novo tightened its full-year guidance to a 4-12% sales decline (from 5-13%). The international expansion is the inflection point for Novo's competitive positioning vs Lilly's Foundayo and the next-generation Mounjaro/Zepbound franchise.
In its fourth commercial week (April 27–May 1), Eli Lilly's Foundayo (orforglipron) recorded 7,335 prescriptions per IQVIA, Citi told clients May 8, calling the early launch 'off to a solid start' and modeling $146M in Q2 revenue and $1.6B for full-year 2026. Citi flagged that IQVIA captures retail and partial telehealth data but likely understates Lilly Direct and the 12+ telehealth firms representing roughly 35% of launch volume; Lilly executives have cited 20,000 patients now on Foundayo. For comparison, Citi's same note pegged Wegovy pill at 440,410 prescriptions in the week ending May 1, with oral semaglutide accounting for 33% of all Novo obesity referrals.
CNBC's May 6 Wegovy-Q1 piece documented LifeMD new-patient volume jumping from 300–400 per day before the Wegovy pill January 5 launch to 600–1,000 per day after, with the telehealth platform crediting the pill format and improved insurance coverage for unlocking a wave of GLP-1-curious patients who had not previously committed to injectables. LifeMD has been one of the most exposed independent pure-play telehealth obesity platforms during the Novo channel-expansion era, and its data point feeds the broader 'oral GLP-1 expands the market' thesis that Lilly's Foundayo team also referenced on the April 30 Q1 call (where 80% of Foundayo patients were new to the GLP-1 class).
Novo Nordisk reported Q1 2026 results May 6: net sales of DKK 96.82B (+24% YoY) and operating profit of DKK 59.62B (+54%). The Wegovy pill drove the print with DKK 2.26B (~$354M) in Q1 sales — almost double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and more than 2 million cumulative US prescriptions since the January 5 launch. Injectable Wegovy sales rose 12% YoY to DKK 18.2B. Ozempic sales fell 8% YoY but came in above expectations. The company tightened full-year guidance to a 4–12% sales-and-operating-profit decline at constant exchange rates, narrower than the prior 5–13% range. NVO US-listed shares rose roughly 6% on the print.
Reuters reported May 5 that Novo Nordisk's Wegovy pill posted roughly 721,000 US prescriptions in Q1 per IQVIA, beating analyst expectations on volume but raising margin questions: about 450,000 of those scripts were for the cheapest 1.5 mg starter dose at $149/month. Lilly's Foundayo approval in early April closed Novo's window as the only oral obesity pill, and Wegovy injection prices have fallen rapidly amid intensifying competition. The Danish company's market value has shed more than $400 billion from its 2024 peak. Wednesday's Q1 print (May 6, 7:30 CEST) is the test: investors are watching whether Novo holds February's guidance of a 5–13% sales and operating-profit decline at constant exchange rates, and whether direct-to-consumer NovoCare and the WW Med+ + GoodRx channels can offset price pressure.
IQVIA data cited by Deutsche Bank analysts and Pharmaphorum showed Novo Nordisk's Wegovy pill at roughly 113,354 prescriptions in its most recent reported week, up from 105,366 the week prior. That puts Novo's January-launched oral semaglutide more than 20× ahead of Lilly's Foundayo Week 3 reading of 5,612, and the gap is from US retail-channel data alone — NovoCare Pharmacy direct-to-consumer volumes are additional. Lilly executives have asked analysts to wait 8–12 weeks for a clearer read, but the early Foundayo-versus-Wegovy-pill comparison continues to favor Novo on raw volume.
Two of the largest obesity drug makers report this week: Eli Lilly (April 30) with Foundayo (orforglipron) launch trajectory and Mounjaro/Zepbound dynamics under scrutiny — Lilly previously guided 2026 sales of $80-83 billion (25% growth); and Novo Nordisk (May 6) facing 5-13% guided sales decline as semaglutide loses exclusivity in China, Brazil, Canada, and as the Wegovy pill ramps. Goldman analysts model Lilly's oral GLP-1 capturing 60% of the daily-oral segment by 2030; Novo's projected at 21%. The Foundayo Week 1-2 prescription tracker has shown a slow start.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.